Earlier this year, a biomedical researcher at the University of Michigan received an update from the National Institutes of Health. The federal agency, which funds a large swath of the country’s medical science, had given the green light to begin releasing funding for the upcoming year on the researcher’s multi-year grant.

Not long after, the researcher learned that the university had placed the grant on hold. The school’s lawyers, it turned out, were wrestling with a difficult question: whether to accept new terms in the Notice of Award, a legal document that outlines the grant’s terms and conditions.

Other researchers at the university were having the same experience. Indeed, Undark’s reporting suggests that the University of Michigan—among the top three university recipients of NIH funding in 2024, with more than $750 million in grants—had quietly frozen some, perhaps all, of its incoming NIH funding dating back to at least the second half of April.

Read full article

Comments

Two years ago, at a Stop & Shop in Rhode Island, the Danish neuroscientist and physician Henriette Edemann-Callesen visited an aisle stocked with sleep aids containing melatonin. She looked around in amazement. Then she took out her phone and snapped a photo to send to colleagues back home.

“It was really pretty astonishing,” she recalled recently.

In Denmark, as in many countries, the hormone melatonin is a prescription drug for treating sleep problems, mostly in adults. Doctors are supposed to prescribe it to children only if they have certain developmental disorders that make it difficult to sleep—and only after the family has tried other methods to address the problem.

Read full article

Comments